In:
Clinical Nuclear Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 46, No. 9 ( 2021-9), p. e475-e477
Abstract:
Patients with unresectable or metastasized neuroendocrine tumors are assumed eligible for PRRT (peptide receptor radionuclide therapy) with 177 Lu-HA-DOTATATE if tumor uptake on somatostatin receptor imaging is higher than normal liver tissue. In our clinic, 2 patients presented with sufficient uptake of 68 Ga-HA-DOTATATE in most metastases but with limited uptake in liver lesions. Posttherapy 177 Lu imaging, however, showed good uptake in all neuroendocrine tumor lesions, including all liver metastases. Therefore, the presence of liver metastases in which the uptake of 68 Ga-HA-DOTATATE is not or only slightly higher than in surrounding normal liver tissue should not be an absolute contraindication for PRRT.
Type of Medium:
Online Resource
ISSN:
1536-0229
,
0363-9762
DOI:
10.1097/RLU.0000000000003618
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2021
detail.hit.zdb_id:
2045053-9
detail.hit.zdb_id:
197628-X
Bookmarklink